Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HIV vaccine vCP1521 - Sanofi Pasteur

Drug Profile

HIV vaccine vCP1521 - Sanofi Pasteur

Alternative Names: ALVAC-HIV-vCP1521; Aventis Pasteur live recombinant ALVAC-HIV (vCP1521) priming vaccine + VaxGen gp120 B/E (AIDSVAX B/E) boosting vaccine; vCP1521

Latest Information Update: 06 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi Pasteur
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III HIV-1 infections

Most Recent Events

  • 04 Mar 2019 Pooled immunogenicity data from the RV305 and RV306 phase II trials in HIV-1 infections presented at the 26th Conference on Retroviruses and Opportunistic Infections (CROI-2019)
  • 31 Jul 2018 Sanofi announces intention to submit regulatory application for HIV 1 infections in 2022
  • 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-1-infections(In infants) in Uganda (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top